CTLA4 and colonic neoplasm: Interestingly, decreasing SPHK1 expression improves the efficacy of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1 therapy) in melanoma, breast, and colon cancer mouse models [18].